Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

"The longer this takes,the more shareholders will get."

Unfortunately, the longer it has taken at ADXS the more shareholder value has eroded due to poor management, unfocused strategy and ongoing dilution. I think if we are able to sell now, it would be the best deal for shareholders, because the "more later" argument, which is what O'Connor was trying to do, has been proven wrong.

I saw an article the other day on Seeking Alpha regarding the sale of Ocata (link below). It's worth a read, basically saying that the company's $400m sale at $8.50 represented a loss to most long term shareholders because of the years of dilution that ultimately over-rode any return on investment the company's shareholders received. It's very reminiscient of ADXS. Just look at our stock price now, it's lower than when Tom Moore was CEO from 2006 to 2013. ADXS is much more advanced now so you'd think investors would have seen an ROI but instead they lost money, it goes to show how poor management and ongoing dilution can wipe out what an investors get even if the company is making some progress. Sell it now, TL and Board, which I think is what's happening given the execu exodus and silence.

"Ocata Therapeutics (NASDAQ:OCAT) has just signed a definitive agreement with Astellas Pharma Inc. (OTCPK:ALPMY) which values OCAT shares at $8.50 each. While this is great news for those who purchased shares in recent months, including yours truly, it would merely be break-even for those who have been hanging on since Ocata (then Advanced Cell Technology) announced its long awaited interim results 13 months ago. For those who bought in the run up associated with Nasdaq listing, the month before, or at many other points in the company's past, it represents a sizable loss."

https://seekingalpha.com/article/3675266-lessons-learned-ocata-others